Correction: Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsRetinal Diseases and Treatments · Retinal and Optic Conditions · Retinal Imaging and Analysis
Notice of Republication
This article was republished on August 7, 2015, to replace Fig 2, which was incorrect. The publisher apologizes for the error. Please download this article again to view the correct version.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F (2015) Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA. P Lo S ONE 10(7): e 0133968 doi: 10.1371/journal.pone.0133968 2620803010.1371/journal.pone.0133968 PMC 4514835 · doi ↗ · pubmed ↗